Page 11 - European Crohn News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Merck s $11B Prometheus Acquisition Brings IBD Drug & Precision Medicine Platform

Merck is acquiring Prometheus Biosciences and a lead drug candidate in development for inflammatory bowel disorders. The deal comes as Merck looks for drug prospects that could make up for revenue declines facing blockbuster seller Keytruda, which faces patent expirations in coming years.

Eli lillyAcceleron pharmaEliav barrColitis organisationMerck research laboratoriesRoivant sciencesBristol myers squibbNektar therapeuticsPrometheus biosciencesSan diego based prometheusEuropean crohnPandion therapeuticsWeight lossMedical devicesHealthcare innovationMedcity news

Merck to Acquire Prometheus Biosciences for $10 8B

Merck & Co. has agreed to acquire Prometheus Biosciences for about $10.8 billion, the companies said Sunday.

United statesSan diegoScott glennStephan targanRobertm davisMark mckennaJanine bilsboroughMichaelj yeeDermotp mcgovernJim laurHealth scienceEuropean medicines agencyMayo collaborative servicesSinai medical centerUs supreme courtSinai technology transfer office

Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc

RAHWAY, N.J. & SAN DIEGO (BUSINESS WIRE) Apr 16, 2023

United statesSan diegoRobertm davisMark mckennaPeter dannenbaumRobert josephsonNoel kurdiMerck co incStatement of merck co incMorgan stanley coCenterview partnersGoldman sachs coColitis organisationWharton garrisonMerck research laboratoriesLatham watkins

Merck Strengthens Immunology Pipeline with Acquisition of

PRA023 is a novel, late-stage candidate for ulcerative colitis and Crohn’s disease and other autoimmune conditions Prometheus Biosciences’.

United statesSan diegoRobert josephsonMark mckennaRobertm davisNoel kurdiPeter dannenbaumPrometheus biosciences incGoldman sachs coExchange commissionStatement of merck co incWharton garrisonColitis organisationCenterview partnersMorgan stanley coLatham watkins

Merck (MRK) to acquire Prometheus Biosciences Inc (RXDX) for $200/share

Merck (MRK) to acquire Prometheus Biosciences Inc (RXDX) for $200/share
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesMark mckennaRobertm davisColitis organisationExchange commissionMerck research laboratoriesCenterview partnersGoldman sachs coPrometheus biosciences incAdvisorsmorgan stanley coWharton garrisonLatham watkinsPrometheus biosciencesEuropean crohnMerck research